3rd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$890,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.

LobbyistCovered position, as disclosed
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 830 (118th), S. 1375 (118th)

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2673 (118th), S. 866 (118th)

Budget/Appropriations BUD

Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.

LobbyistCovered position, as disclosed
HANNAH BETH CORNWELL New Intern, Sen. Rubio (2018); Staff Assistant, Sen. McCain (2018); SA, LC, LA, Sen. Alexander (2018-2020); LC, La, LA, Sen. Kennedy (2020-2023).
KRISTIN RICHTER —
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.